文献速递类风湿关节炎

BeSt与IMPROVED研究中达标治疗的早期类风湿关节炎长期临床结局

Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

评估BeSt和IMPROVED试验中达标治疗的早期类风湿关节炎或未分化关节炎患者20年和12年后的疾病结局。BeSt纳入508例早期RA患者随机分四组治疗,目标为低疾病活动度(DAS≤2.4);IMPROVED纳入610例早期RA/UA患者起始MTX联合泼尼松桥接,目标为缓解(DAS<1.6)。随访时91%达低疾病活动度,68%处于DAS缓解,影像学进展轻微但未完全抑制。

要点

  • 随访时91%患者达低疾病活动度,68%处于DAS缓解。
  • ex-BeSt中位SHS为14.0,自BeSt结束进展6.0;ex-IMPROVED中位SHS为8,自IMPROVED结束进展4。
  • ex-BeSt平均HAQ为0.8±0.6,ex-IMPROVED为0.6±0.6。

核心结论

  • 治疗开始后12/20年,多数达标治疗至低DAS或DAS缓解的RA和UA患者处于DAS缓解且功能残疾有限。
  • 影像学损伤进展轻微但未完全抑制。

研究设计与样本

  • BeSt试验(纳入2000-02年, duration 10年)将508例早期RA患者随机分为四组:1.序贯单药治疗,2.阶梯联合治疗,3.初始csDMARD联合治疗,4.初始bDMARD/csDMARD联合治疗,治疗目标为低疾病活动度(DAS≤2.4)。
  • IMPROVED试验(纳入2007-10年, duration 5年)纳入610例早期RA/UA患者,起始MTX联合泼尼松桥接,治疗目标为缓解(DAS<1.6);未早期缓解者随机分为1.csDMARD联合治疗或2.bDMARD/csDMARD联合治疗。
  • 2019至22年间邀请这些患者进行长期随访,153例ex-BeSt和282例ex-IMPROVED患者参与,距研究开始中位时间分别为12年和20年。

主要发现

  • ex-BeSt和ex-IMPROVED患者中,低疾病活动度率为91%,68%处于DAS缓解。
  • ex-BeSt中位SHS为14.0(IQR 6.0-32.5;自BeSt结束进展6.0,IQR 2.0-12.5),ex-IMPROVED中位SHS为8(IQR 3-16;自IMPROVED结束进展4,IQR 2-9)。
  • ex-BeSt平均HAQ为0.8±0.6(自BeSt结束变化:0.3±0.5),ex-IMPROVED平均HAQ为0.6±0.6(自IMPROVED结束变化:0.06±0.5)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess disease outcomes after 20 and 12 years of patients with RA or undifferentiated arthritis (UA), treated-to-target in the BeSt and IMPROVED trials. METHODS: In BeSt (inclusion 2000-02, duration 10 years), 508 patients with early RA were randomized to: 1. sequential monotherapy, 2. step-up combination therapy, 3. initial csDMARD combination therapy, 4. initial bDMARD/csDMARD combination therapy. The treatment target was low disease activity (DAS ≤ 2.4).In IMPROVED (inclusion 2007-10, duration 5 years), 610 patients with early RA/UA started MTX with prednisone bridging. The treatment target was remission (DAS < 1.6). Patients not in early remission were randomized to 1. csDMARD combination therapy or 2. bDMARD/csDMARD combination therapy.Between 2019 and 22, these patients were invited for long-term follow-up. RESULTS: One-hundred-fifty-three ex-Best and 282 ex-IMPROVED patients participated in the follow-up study after a median of 12 and 20 years since the study started.In ex-BeSt and ex-IMPROVED patients, the rate of low disease activity was 91%, and 68% were in DAS remission. Median SHS was 14.0 in ex-BeSt (IQR 6.0-32.5; progression since end BeSt 6.0, IQR 2.0-12.5) and 8 in ex-IMPROVED participants (IQR 3-16; progression since end IMPROVED 4, IQR 2-9). Mean HAQ was 0.8 ± 0.6 in ex-BeSt (change since end BeSt: 0.3 ± 0.5) and 0.6 ± 0.6 in ex-IMPROVED participants (change since end IMPROVED: 0.06 ± 0.5). CONCLUSION: At 12/20 years after treatment started, the majority of RA and UA patients who had been treated to target low DAS or DAS remission were in DAS remission and had limited functional disability. Radiographic damage progression was mild although not completely suppressed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Heckert SL, Maassen JM, Nevins I, et al. Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies. Rheumatology (Oxford). 2025. PMID: 38561181. doi:10.1093/rheumatology/keae212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。